Translate
Alterity Therapeutics Ltd
About
Alterity Therapeutics Ltd (AU:ATH) — investor relations, events, news, and company updates on 6ix.
Latest News
Today
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
Apr 22 2026
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
Apr 17 2026
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
Apr 16 2026
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
Apr 15 2026
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
Recent Videos
Alterity Therapeutics adds industry veteran to board
Apr 17, 2026
Alterity Therapeutics (ASX: ATH) Presentation | NWR Virtual Healthcare Conference
Mar 25, 2026
From the helm: Alterity Therapeutics (ASX:ATH), CEO, David Stamler.
Mar 19, 2026
Why This ASX Biotech is Dominating the Race to Cure "Parkinson’s Plus"
Mar 17, 2026